Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 4, 2015, Pages 1137-1142

  Yang, Chunzhang ^a   Wang, Herui ^a   Zhu, Dongwang ^a   Hong, Christopher S ^a   Dmitriev, Pauline ^a   Zhang, Chao ^a   Li, Yan ^a   Ikejiri, Barbara ^a   Brady, Roscoe O ^a   Zhuang, Zhengping ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Gaucher disease; Heat shock protein; Hsp27; Hsp90; Molecular chaperone

Indexed keywords

CHAPERONE; GLUCOSYLCERAMIDASE; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; PEPTIDE; PROTEASOME; ATP DEPENDENT 26S PROTEASE; CDC37 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CHAPERONIN; HOMEODOMAIN PROTEIN; HOP PROTEIN, HUMAN; HSPB1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GAUCHER DISEASE; HUMAN; HUMAN CELL; MUTANT; PRIORITY JOURNAL; PROTEASOMAL DEGRADATION; PROTEIN DEGRADATION; GENETICS; HELA CELL LINE; METABOLISM; MUTATION; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCY;

CELL CYCLE PROTEINS; CHAPERONINS; FIBROBLASTS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HELA CELLS; HOMEODOMAIN PROTEINS; HSP27 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; PROTEOLYSIS; PROTEOSTASIS DEFICIENCIES; TUMOR SUPPRESSOR PROTEINS;

EID: 84921717897     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424288112     Document Type: Article

References (26)

1. Horowitz M, Zimran A (1994) Mutations causing Gaucher disease. Hum Mutat 3(1):1-11.
2. Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29(5):567-583.
3. Lu J, et al. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci USA 108(52):21200-21205.
4. Lu J, et al. (2010) Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci USA 107(50):21665-21670.
5. Babajani G, Tropak MB, Mahuran DJ, Kermode AR (2012) Pharmacological chaperones facilitate the post-ER transport of recombinant N370Smutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant. Mol Genet Metab 106(3):323-329.
6. Ron I, Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14(16):2387-2398.
7. Ron I, Rapaport D, Horowitz M (2010) Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum Mol Genet 19(19):3771-3781.
8. Maor G, Filocamo M, Horowitz M (2013) ITCH regulates degradation of mutant glucocerebrosidase: implications to Gaucher disease. Hum Mol Genet 22(7):1316-1327.
9. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA (1993) Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 85(19):1558-1570.
10. Parcellier A, et al. (2003) HSP27 is a ubiquitin-binding protein involved in I-kappa-Balpha proteasomal degradation. Mol Cell Biol 23(16):5790-5802.
11. Parcellier A, et al. (2006) HSP27 favors ubiquitination and proteasomal degradation of p27Kip1 and helps S-phase re-entry in stressed cells. FASEB J 20(8):1179-1181.
12. Ho Y, et al. (2002) Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415(6868):180-183.
13. Yang C, et al. (2013) Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci USA 110(3):966-971.
14. Yang C, et al. (2014) Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones. Proc Natl Acad Sci USA 111(1):249-254.
15. Tan YL, et al. (2014) ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease. Chem Biol 21(8):967-976.
16. Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG (2011) Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leukemia 11(1):17-22.
17. Roh JL, Kim EH, Park HB, Park JY (2013) The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer. Cell Death Dis 4:e956.
18. Powers MV, et al. (2013) Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget 4(11):1963-1975.
19. Bendikov-Bar I, Rapaport D, Larisch S, Horowitz M (2014) Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS. Orphanet J Rare Dis 9:86.
20. Helquist P, Maxfield FR, Wiech NL, Wiest O (2013) Treatment of Niemann-pick type C disease by histone deacetylase inhibitors. Neurotherapeutics 10(4):688-697.
21. Yang C, et al. (2012) Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB J 26(11):4506-4516.
22. Yang C, et al. (2011) Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci USA 108(12):4980-4985.
23. Bendikov-Bar I, Horowitz M (2012) Gaucher disease paradigm: from ERAD to comorbidity. Hum Mutat 33(10):1398-1407.
24. Bendikov-Bar I, Ron I, Filocamo M, HorowitzM(2011) Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis 46(1):4-10.
25. Knapinska AM, et al. (2011) Chaperone Hsp27 modulates AUF1 proteolysis and AUrich element-mediated mRNA degradation. Mol Cell Biol 31(7):1419-1431.
26. Yang C, et al. (2012) β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci USA 109(18):6963-6968.